View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
December 21, 2018

M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals

Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.

Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.

Astellas made an upfront payment of $164.6m and has agreed to make an additional payment of up to $240.1m based on the progress of Potenza’s clinical development programmes.

The acquisition was completed under a collaboration agreement signed between the two companies in 2015. The two companies discovered and developed three investigational new drugs, namely ASP8374/PTZ-201, ASP1948/PTZ-329, and ASP1951/PTZ-522, under the collaboration.

Based in Japan, Astellas Pharma focuses on the development of pharmaceutical products in therapeutic fields, while Potenza Therapeutics is a US-based preclinical-stage biotechnology company focused on building a portfolio of oncology.

Taisho Pharmaceutical has announced plans to acquire Bristol-Myers Squibb’s UPSA consumer health business for $1.6bn.

Taisho will acquire UPSA and Bristol-Myers Squibb’s assets and liabilities associated with the consumer health business product portfolio.

“The acquisition will add Perosphere’s anticoagulant reversal agent, ciraparantag, to AMAG’s product pipeline.”

The transaction is expected to be completed in the first half of 2019, subject to regulatory approvals and customary closing conditions.

Taisho is a Japanese manufacturer of over-the-counter (OTC) medicines and health-related products, while Bristol-Myers Squibb is a US-based biopharmaceutical company.

AMAG Pharmaceuticals has signed a definitive agreement to acquire Perosphere Pharmaceuticals.

AMAG will pay $50m to Perosphere’s equity holders and assume $12m term loan and up to $6.2m of Perosphere’s liabilities, upon completion of the acquisition.

The acquisition will add Perosphere’s anticoagulant reversal agent, ciraparantag, to AMAG’s product pipeline.

Perosphere’s equity holders will be eligible to receive regulatory milestone-based payments of up to $140m upon the European Medicines Agency’s (EMA) approval of the drug, as well as up to $225m in commercial sales milestones. The first payment of $20m will be paid upon achieving annual sales of $100m.

AMAG Pharmaceuticals is a pharmaceutical company focused on therapeutic areas and women’s health, while Perosphere Pharmaceuticals is engaged in addressing unmet medical needs associated with anticoagulant therapies.

Both companies are based in the US.

Merck has entered a definitive agreement to acquire Antelliq Group.

Merck will pay €2.1bn ($2.38bn) to acquire all the outstanding shares of Antelliq and also assume €1.15bn ($1.3bn) of Antelliq’s debt, which it plans to repay after closing the transaction.

Antelliq will operate as a wholly owned subsidiary of Merck within the Merck Animal Health Division, upon completion of the acquisition.

The transaction is subject to antitrust and regulatory clearance and is expected to be closed in the second quarter of 2019.

Based in US, Merck is a biopharmaceutical company engaged in producing medicines, vaccines, biologic therapies, and animal health products, while Antelliq Group is a France-based pharmaceutical company focused on design, production, and distribution of animal intelligence solutions.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology